Daily Brief Australia: S&P/ASX 200, Coro Energy PLC, Telix Pharmaceuticals and more

In today’s briefing:

S&P/ASX 200: Profit Targets After Sep-25 Rebalance Methodology Finalized

As reported by Brian Freitas , 2 days ago S&P DJI confirmed that the proposals in the market consultation will be implemented at the September 25 rebalance. Details here.
The S&P/ASX 200 (AS51 INDEX) is currently OVERBOUGHT according to our models: the index reached an 83% probability of reversal at the intraweek high (9025). Incoming pullback.
The index could rally one more week (next week), that should be the end of this rally (short-term forecast), but could also pull back this week, checkour modelkey-supports.

The financial components of the regenerative funding are completed, raising a combined £1.68m via a Placing and an open WRAP Retail offer at 0.5p.
The funding, representing 41.1% of the issued share capital, will accelerate the roll-out of the rooftop solar energy in Vietnam aiming to provide high margin, sustainable, long term cashflows from credit worthy Commercial and Industrial (C&I) customers.
Vietnam has a clean energy agenda as it transitions away from coal and fossil fuels to produce 28-36% of its 560.4bn KW per annum power usage in renewables by 2030.

For 1H25, Telix Pharmaceuticals (TLX AU) recorded revenue of $390M, up 63% YoY and 41% HoH. Even after excluding RLS revenue, base business revenue grew 30% YoY and 12% HoH.
Illuccix continues to drive revenue growth. Global sales of Illuccix were $306M in 1H25, up 29% YoY, reflecting continued growth in sales volume and market share gains in the U.S.
SEC subpoena has not affected the normal business operation. Telix is “fully cooperating with the SEC and is in the process of responding to the information request.”

💡 Before it’s here, it’s on Smartkarma

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network